Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.

License
https://creativecommons.org/licenses/by/4.0

Type
Article

Authors
Weerts, Marjolein J A
Lanko, Kristina
Guzmán-Vega, Francisco J.
Jackson, Adam
Ramakrishnan, Reshmi
Cardona-Londoño, Kelly J
Peña-Guerra, Karla A
van Bever, Yolande
van Paassen, Barbara W
Kievit, Anneke
van Slegtenhorst, Marjon
Allen, Nicholas M
Kehoe, Caroline M
Robinson, Hannah K
Pang, Lewis
Banu, Selina H
Zaman, Mashaya
Efthymiou, Stephanie
Houlden, Henry
Järvelä, Irma
Lauronen, Leena
Määttä, Tuomo
Schrauwen, Isabelle
Leal, Suzanne M
Ruivenkamp, Claudia A L
Barge-Schaapveld, Daniela Q C M
Peeters-Scholte, Cacha M P C D
Galehdari, Hamid
Mazaheri, Neda
Sisodiya, Sanjay M
Harrison, Victoria
Sun, Angela
Thies, Jenny
Pedroza, Luis Alberto
Lara-Taranchenko, Yana
Chinn, Ivan K
Lupski, James R
Garza-Flores, Alexandra
McGlothlin, Jeffery
Yang, Lin
Huang, Shaoping
Wang, Xiaodong
Jewett, Tamison
Rosso, Gretchen
Lin, Xi
Mohammed, Shehla
Merritt, J Lawrence
Mirzaa, Ghayda M
Timms, Andrew E
Scheck, Joshua
Elting, Mariet W
Polstra, Abeltje M
Schenck, Lauren
Ruzhnikov, Maura R Z
Vetro, Annalisa
Montomoli, Martino
Guerrini, Renzo
Koboldt, Daniel C
Mosher, Theresa Mihalic
Pastore, Matthew T
McBride, Kim L
Peng, Jing
Pan, Zou
Willemsen, Marjolein
Koning, Susanne
Turnpenny, Peter D
de Vries, Bert B A
Gilissen, Christian
Pfundt, Rolph
Lees, Melissa
Braddock, Stephen R
Klemp, Kara C
Vansenne, Fleur
van Gijn, Marielle E
Quindipan, Catherine
Deardorff, Matthew A
Hamm, J Austin
Putnam, Abbey M
Baud, Rebecca
Walsh, Laurence
Lynch, Sally A
Baptista, Julia
Person, Richard E
Monaghan, Kristin G
Crunk, Amy
Keller-Ramey, Jennifer
Reich, Adi
Elloumi, Houda Zghal
Alders, Marielle
Kerkhof, Jennifer
McConkey, Haley
Haghshenas, Sadegheh
Genomics England Research Consortium
Maroofian, Reza
Sadikovic, Bekim
Banka, Siddharth
Barakat, Tahsin Stefan
Barakat, Tahsin Stefan

KAUST Department
Bioengineering
Biological and Environmental Science and Engineering (BESE) Division
Bioscience Program
Computational Bioscience Research Center (CBRC)
Structural Biology and Engineering

KAUST Grant Number
FCC/1/1976-25
REI/1/4446-01

Online Publication Date
2021-08-03

Print Publication Date
2021-11

Date
2021-08-03

Submitted Date
2021-03-05

Abstract
PurposePathogenic variants in SETD1B have been associated with a syndromic neurodevelopmental disorder including intellectual disability, language delay, and seizures. To date, clinical features have been described for 11 patients with (likely) pathogenic SETD1B sequence variants. This study aims to further delineate the spectrum of the SETD1B-related syndrome based on characterizing an expanded patient cohort.MethodsWe perform an in-depth clinical characterization of a cohort of 36 unpublished individuals with SETD1B sequence variants, describing their molecular and phenotypic spectrum. Selected variants were functionally tested using in vitro and genome-wide methylation assays.ResultsOur data present evidence for a loss-of-function mechanism of SETD1B variants, resulting in a core clinical phenotype of global developmental delay, language delay including regression, intellectual disability, autism and other behavioral issues, and variable epilepsy phenotypes. Developmental delay appeared to precede seizure onset, suggesting SETD1B dysfunction impacts physiological neurodevelopment even in the absence of epileptic activity. Males are significantly overrepresented and more severely affected, and we speculate that sex-linked traits could affect susceptibility to penetrance and the clinical spectrum of SETD1B variants.ConclusionInsights from this extensive cohort will facilitate the counseling regarding the molecular and phenotypic landscape of newly diagnosed patients with the SETD1B-related syndrome.

Citation
Weerts, M. J. A., Lanko, K., Guzmán-Vega, F. J., Jackson, A., Ramakrishnan, R., Cardona-Londoño, K. J., … Kievit, A. (2021). Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome. Genetics in Medicine. doi:10.1038/s41436-021-01246-2

Acknowledgements
We thank all patients and families for participation in this study. Part of this research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK, and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Family 2 was collected as part of the SYNaPS Study Group collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding (WT093205 MA and WT104033aIA) and research was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. HH is funded by The MRC (MR/S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetree Trust, Ataxia UK, MSA Trust, Brain Research UK, Sparks GOSH Charity, Muscular Dystrophy UK (MDUK), Muscular Dystrophy Association (MDA USA). G.M.M. was supported by Jordan’s Guardian Angels, the Brotman Baty Institute, and the Sunderland Foundation. J.R.L. acknowledges support by the Baylor Hopkins Center for Mendelian Genomics funded by the US National Human Genome Research Institute (UM1 HG006542). The DECODE-EE project (Health Research Call 2018, Tuscany Region) provided research funding to R.G. The Epilepsy Society supported this work, with funding to S.M.S. S.M.S. acknowledges that his work was partly carried out at NIHR University College London Hospitals Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. A.J. is supported by Solve-RD. The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. STA, R.R., K.J.C.L., K.A.P.G., and F.J.G.V. were supported by funding from King Abdullah University of Science and Technology (KAUST) through the baseline fund and award numbers FCC/1/1976-25 and REI/1/4446-01 from the Office of Sponsored Research (OSR). T.S.B.’s lab is supported by the Netherlands Organisation for Scientific Research (ZonMW Veni, grant 91617021), a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation, an Erasmus MC Fellowship 2017, and Erasmus MC Human Disease Model Award 2018.

Publisher
Springer Science and Business Media LLC

Journal
Genetics in Medicine

DOI
10.1038/s41436-021-01246-2

PubMed ID
34345025

Additional Links
https://www.nature.com/articles/s41436-021-01246-2

Permanent link to this record

Version History

Now showing 1 - 2 of 2
VersionDateSummary
2*
2021-08-08 12:23:21
Published in journal
2021-02-24 12:16:02
* Selected version